Glatiramer acetate for multiple sclerosis: A comprehensive review of mechanisms and clinical efficacy

Marina Zvartau-Hind, Christina Caon, Rana Zabad, Alexandros Tselis, Robert Lisak, Omar Khan

Research output: Contribution to journalReview articlepeer-review

3 Scopus citations


The 'Decade of the Brain' (1990-2000) saw unprecedented advances in neurosciences including multiple sclerosis. It could have not been more aptly named, as it produced a shift in the paradigm of multiple sclerosis management, making multiple sclerosis a treatable disorder with the availability of several therapeutic options. For a chronic progressive neurological disorder like multiple sclerosis, this change in the understanding and treatment touched the lives of hundreds of thousands of patients worldwide and many more who provided care and counsel as family and friends. Of the four agents available for the treatment of the most common type of multiple sclerosis - relapsing-remitting - three are β-interferons and one is a noninterferon polypeptide of four amino acids (glatiramer acetate) with a distinct immunomodulating profile. Glatiramer acetate is now approved and available in North America, Europe and many other countries. It has been tested in pivotal trials as well as long term extension trials for almost 10 years (8 years published) providing remarkable evidence of efficacy and safety. This review will highlight the immune mechanisms and clinical data reported with glatiramer acetate in multiple sclerosis over the past three decades.

Original languageEnglish (US)
Pages (from-to)285-294
Number of pages10
JournalExpert Review of Neurotherapeutics
Issue number3
StatePublished - 2002
Externally publishedYes


  • Clinical trials
  • Copaxone
  • Copolymer 1
  • Glatiramer acetate
  • Multiple sclerosis
  • Relapsing-remitting

ASJC Scopus subject areas

  • Neuroscience(all)
  • Clinical Neurology
  • Pharmacology (medical)


Dive into the research topics of 'Glatiramer acetate for multiple sclerosis: A comprehensive review of mechanisms and clinical efficacy'. Together they form a unique fingerprint.

Cite this